Drug Profile


Alternative Names: 4-HAD; 4-Hydroxyandrostenedione; 4-OHA; AT 0931; CGP 32349; CRC 8201; CRC-82/01; Formestane IM depot injection; Lentaron

Latest Information Update: 19 Jul 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Androstenes; Antineoplastics; Ketosteroids; Small molecules
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Breast cancer

Most Recent Events

  • 19 Jul 2010 Development discontinued for Breast cancer during 2001
  • 07 Mar 2003 A study has been added to the Cancer therapeutic trials section
  • 27 Apr 1999 Clinical data have been added to the therapeutic trials, pharmacodynamics and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top